Centralna tehniška knjižnica Univerze v Ljubljani (CTK)
  • Systemic therapy of advanced non-small cell lung cancer : major-developments of the last 5-years
    Čufer, Tanja ; Ovčariček, Tanja ; O'Brien, Mary E. R.
    The standard palliative treatment for advanced stage NSCLC remains a platinum doublet but by tailoring chemotherapy according to tumour histology the results can be improved through using ... pemetrexed-containing schemas in non-squamous-cell disease. In addition, maintenance chemotherapy appears to be effective in patients achieving clinical benefit by induction therapy. Targeted therapy based on the presence of activating epidermal growth factor receptor (EGFR) activating mutations or EML4-ALK gene rearrangement is becoming standard practice with high median survival rates, up to 30 months. There are still numerous other molecular targeted drugs in development. This review presents the most recent relevant progress in systemic anti-cancer therapy of advanced NSCLC in the past 5 years and delineates today's new treatment options.
    Vir: European Journal of Cancer. - ISSN 0959-8049 (49, 2013, str. 1216-1225)
    Vrsta gradiva - članek, sestavni del
    Leto - 2013
    Jezik - angleški
    COBISS.SI-ID - 36823557

vir: European Journal of Cancer. - ISSN 0959-8049 (49, 2013, str. 1216-1225)

loading ...
loading ...
loading ...